MedTrace Logo

The PACE-MI Registry Study - Outcomes of Beta-blocker Therapy After Myocardial Infarction (OBTAIN)

NCT00430612 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 7057

Last updated 2023-04-24

No results posted yet for this study

Summary

The purpose of the PACE-MI (OBTAIN) registry is:

* Analyze beta-blocker dose response effect on outcome over two years
* Explore gender and minority differences in beta-blocker utilization and outcomes.

In patients with Myocardial Infarction (MI) discharged from the hospital, beta-blocker dose will be predictive of survival.

Exploratory analyses: Gender and racial effects-gender and race are, similarly, hypothesized to be predictive of post-MI survival.

The existence of interactions between gender and beta-blocker effect as well as race and beta-blocker effect will also be evaluated.

Conditions

Sponsors & Collaborators

Principal Investigators

  • Jeffrey Goldberger, MD, MBA · Northwestern University

Eligibility

Min Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-05-31
Primary Completion
2013-12-31
Completion
2015-10-31

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00430612 on ClinicalTrials.gov